Skip to main content
Article thumbnail
Location of Repository

TNF-related apoptosis inducing ligand in ocular cancers and ocular diabetic complications

By Paolo Perri, Giorgio Zauli, Arianna Gonelli, Daniela Milani, Claudio Celeghini, Giuseppe Lamberti and Paola Secchiero


TNF-related apoptosis inducing ligand (TRAIL) is an intensively studied cytokine, in particular for its anticancer activity. The discovery that conjunctival sac fluid contains extremely high levels of soluble TRAIL as compared to other body fluids suggested important implications in the context of the immunological surveillance of the eye, in particular of the anterior surface. In this review, we discuss the potential physiopathologic and therapeutic role of the TRAIL/TRAIL receptor system in a variety of ocular cancers. Moreover, since an increasing amount of data has indicated the important biological activities of the TRAIL/TRAIL receptor systems also in a completely different pathologic context such as diabetes mellitus, in the second part of this review we summarize the currently available data on the involvement of TRAIL in the ocular complications of diabetes mellitus as modulator of the inflammatory and angiogenic response in the eye

Topics: TNF-Related Apoptosis Inducing Ligand, ocular cancer
Year: 2015
DOI identifier: 10.1155/2015
OAI identifier:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.